ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) announced its earnings results on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.10, Zacks reports.
ESSA Pharma Trading Up 3.6 %
Shares of EPIX traded up $0.16 during mid-day trading on Wednesday, hitting $4.62. The company’s stock had a trading volume of 332 shares, compared to its average volume of 94,939. ESSA Pharma has a 52-week low of $2.58 and a 52-week high of $11.67. The company’s 50-day moving average is $5.26 and its 200-day moving average is $7.05. The firm has a market capitalization of $204.94 million, a price-to-earnings ratio of -7.08 and a beta of 1.82.
Analyst Upgrades and Downgrades
Separately, Oppenheimer reiterated an “outperform” rating and set a $17.00 price target on shares of ESSA Pharma in a report on Thursday, May 16th.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Further Reading
- Five stocks we like better than ESSA Pharma
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Nuclear Power Giant’s Shares Jump on Raised Full-Year Guidance
- Where Do I Find 52-Week Highs and Lows?
- Airbnb Stock: Key Drivers Indicate Bright Future Despite Sell-Off
- Upcoming IPO Stock Lockup Period, Explained
- Amgen’s MariTide Weight Loss Potential: Stock Outlook
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
